Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared on X:
“Major unmet need for Mutant Specific PIK3CA inhibitors with improved efficacy and side effects for our patients.
RLY2608 and Fulvestrant in post-CDK4/6 HR+, HER2- PIK3CA mutant breast cancer.
ORR close to 40% post-CDK4/6.
Median PFS 10 months all comers, 11 months 2L, 18 months kinase mutant.
Side effects mostly low grade: hyperglycemia, nausea, fatigue. Little rash, oral mucositis, diarrhea.
Phase III opening at sites next week!”
You can find more posts featuring Sarah Sammons on OncoDaily.